Each Situation Is Different

This brochure is intended to answer some common questions about Gleolan. It does not contain all the available information, so let your doctor know of any questions or concerns you may have.

Gleolan is known as an “optical imaging agent” that is taken by patients before surgery to help neurosurgeons to see certain brain tumors, known as “high-grade gliomas.”¹

Please see the enclosed full Prescribing Information.

LEARN MORE AT GLEOLAN.COM
Removing the Tumor During Surgery

• As part of your treatment plan, your neurosurgeon will be performing surgery to remove as much of your tumor as they can safely remove. This is known as “resection.” The amount of tumor that can be removed is determined by the tumor’s size and location.

• Neurosurgeons have several tools that are helpful for locating the tumor during surgery; these tools provide information that allows for removal of as much tumor tissue as possible.

Gliomas generally have very small cells that grow into brain tissue, which may make them difficult to see and resect.

• The goal is to remove as much of the tumor as possible without harming areas of the brain that control critical functions such as speech or balance.

PATIENT SAFETY INFORMATION

Gleolan can cause a sunburn-type skin reaction, also referred to as photosensitivity. Do not take any drugs that may worsen this (such as St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines) and do not put anything on your skin that contains aminolevulinic acid (ALA) for 24 hours before and for 24 hours after receiving Gleolan.

Please see the enclosed full Prescribing Information.
Using Gleolan in Neurosurgery

For your surgery, your neurosurgeon may use Gleolan® (aminolevulinic acid HCl).

- Gleolan is known as an “optical imaging agent” that you take before surgery to help neurosurgeons see certain brain tumors known as “high-grade gliomas”¹

- Gleolan is an oral solution that you will drink 3 hours (between 2 to 4 hours) before you receive anesthesia for your surgery. It contains aminolevulinic acid hydrochloride (ALA HCl)¹

During the surgery, your neurosurgeon will view the brain through special blue light filters on the surgical microscope.¹

Under this blue light, Gleolan helps the tumor “fluoresce” or glow a red-violet color.

- Since cancerous brain cells glow under the blue light with Gleolan, the neurosurgeon will be better able to tell the difference between the tumor tissue and normal tissue (see image above)¹

- This may allow the neurosurgeon to remove more of the tumor tissue and spare healthy tissue¹

LEARN MORE AT GLEOLAN.COM
Common Questions About Gleolan

WHAT IS GLEOLAN® (aminolevulinic acid HCl) FOR?

Gleolan is known as an “optical imaging agent” that is taken by patients before surgery to help neurosurgeons to see certain brain tumors known as “high-grade gliomas.”

IS THERE ANYONE WHO SHOULD NOT TAKE GLEOLAN?

You should not take Gleolan if you have an allergy to any medicine containing aminolevulinic acid or porphyrins or have a condition called porphyria.

Tell your doctor about any allergies or conditions that you have and mention all medications that you are currently taking. If you are pregnant, breastfeeding, or suspect that you may be pregnant, let your doctor know. Your doctor can discuss with you the risks and benefits involved.

PATIENT SAFETY INFORMATION (continued)

Errors may occur with the use of Gleolan to see tumors. Sometimes brain tumor cells may fluoresce even if they are not cancerous or those that are cancerous may not fluoresce. Also, cancer cells from other tumors or areas of swelling may fluoresce.

Please see the enclosed full Prescribing Information.
Even though the active chemical in Gleolan is already in your body, you may experience some side effects from Gleolan. Tell your doctor if you experience any unusual symptoms or reactions.\(^1\)

The types of reactions that occurred in some patients in the week after surgery were fever (pyrexia), decrease in blood pressure (hypotension), nausea, and vomiting.\(^1\)

Disorders that affect the nervous system happened in a small percentage of patients in the first weeks after surgery. These included: a total or partial loss of ability to use or understand language (aphasia), partial paralysis of one side of the body (hemiparesis), blindness for half the field of vision in one or both eyes (hemianopsia), headache, seizure, paralysis of one side of the body (hemiplegia), paralysis of a single limb (monoparesis), and reduced sense of touch (hypoesthesia). Swelling of the brain (brain edema) occurred in a small percentage of patients in the first 6 weeks after surgery. Neurologic events related to the surgical procedure occurred in 29% of patients and included headache, seizure, moderate loss of sensory and motor function, and swelling of the brain (brain edema). The changes in neurologic function returned to the same as the non-treated group during the weeks after surgery.\(^1\)

Inflammation or damage to your liver is possible within the first week after surgery (and may continue beyond 6 weeks). This should be monitored carefully by your doctor.\(^1\)

You are encouraged to report any side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
PATIENT SAFETY INFORMATION (continued)

Allergic reactions, including serious allergic reactions, to Gleolan have occurred. Your medical team should monitor you for this and should have emergency equipment ready to manage any such reaction if it occurs.

Please see the enclosed full Prescribing Information.

TAKING GLEOLAN® (aminolevulinic acid HCl)

Your doctor and the team in the hospital will determine how much Gleolan you should take based on your body weight and will prepare a Gleolan solution for you to drink 3 hours (between 2 to 4 hours) before you receive anesthesia. Be sure to carefully follow all directions given to you by your medical team. The liquid is clear/yellowish and has a sour taste.¹

WHAT IS PHOTOSENSITIVITY?

Gleolan makes you more sensitive to sunlight and direct indoor lighting, which is referred to as photosensitivity, and can cause a sunburn-type reaction. The hospital team will make sure you are kept in low-light conditions from the time you take Gleolan until you are discharged. You should maintain these low-light conditions at home and avoid sunlight until 48 hours from the time you took Gleolan. You may wish to bring a hat and clothing to the hospital so that your body can be completely covered when you are discharged.¹

You will also need to avoid certain drugs that may worsen a potential sunburn-type reaction (such as St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines) and not put anything on your skin that contains ALA for 24 hours before and for 24 hours after taking Gleolan. Ask your medical team if you have any questions about this.¹

PATIENT SAFETY INFORMATION (continued)

Allergic reactions, including serious allergic reactions, to Gleolan have occurred. Your medical team should monitor you for this and should have emergency equipment ready to manage any such reaction if it occurs.

Please see the enclosed full Prescribing Information.
 WHEN WAS GLEOLAN APPROVED?

Gleolan was approved in the United States by the Food and Drug Administration (FDA) in 2017. In other countries, it was approved as early as 2007. To date, more than 100,000 patients have received this drug worldwide.\(^1\),\(^2\)

 IS GLEOLAN COVERED BY INSURANCE?

Gleolan is considered part of the surgical procedure and is covered through payment to the hospital. Contact your healthcare insurer with questions regarding coverage of Gleolan.

Please see your doctor if you have any questions or concerns about Gleolan
**WILL GLEOLAN® AFFECT TREATMENT THAT I RECEIVE AFTER SURGERY?**

Use of Gleolan does not affect the use of other treatments for your cancer such as radiotherapy or chemotherapy.

**DOES GLEOLAN TREAT CANCER?**

Gleolan is not a treatment for cancer. Its use, as approved by the FDA, is to assist the neurosurgeon during surgery to see the brain tumor to enable safe removal of as much of it as possible.¹

**PATIENT SAFETY INFORMATION**

Gleolan can cause a sunburn-type skin reaction, also referred to as photosensitivity. Do not take any drugs that may worsen this (such as St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines) and do not put anything on your skin that contains aminolevulinic acid (ALA) for 24 hours before and for 24 hours after receiving Gleolan.

Please see the enclosed full Prescribing Information.

GLEOLAN® (aminolevulinic acid hydrochloride) for oral solution

GLEAN is a colorless to slightly yellowish in color. (3)

Dosage and Administration

For oral solution: 1,500 mg aminolevulinic acid hydrochloride lyophilized powder, equivalent to 1,370 mg aminolevulinic acid per vial. The reconstituted aminolevulinic acid hydrochloride solution contains 50 mg per ml and is clear and colorless to slightly yellowish in color. (3)

Adverse Reactions

Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausia, and vomiting. (6.1)

2.1 Recommended Dose

For oral use only

• Recommended oral dose of Gleenan is 20 mg/kg. (2.1)

• Administer Gleenan to patient orally 3 hours (range 2 to 4 hours) before anesthesia. (2.1)

• See Full Prescribing Information for reconstitution information. (2.2)

• Use appropriate visualization techniques with appropriate surgical microscopes and light source filters. (2.4)

Dosage Forms and Strengths

For oral solution: 1,500 mg aminolevulinic acid hydrochloride lyophilized powder, equivalent to 1,370 mg aminolevulinic acid per vial. The reconstituted aminolevulinic acid hydrochloride solution contains 50 mg per ml and is clear and colorless to slightly yellowish in color. (3)

Contraindications

• Hypersensitivity to aminolevulinic acid (ALA) or porphyrins. (4, 5.3, 6.2)

• Acute or chronic types of porphyria. (4)

Full Prescribing Information: Contents

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

2.2 Reconstitution of Gleenan

2.3 Gleenan Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Phototoxic Reaction

5.2 Risk of Misinterpretation

5.3 Hypersensitivity Reactions

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

6.2 Post Marketing Experience

6.3 Drug Interactions

6.4 Use in Specific Populations

8.1 Pregnancy

8.2 Lactation

WARNINGS AND PRECAUTIONS

• Phototoxic reactions: Do not administer phototoxic drugs (St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolines and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after oral administration of Gleenan. (5.1, 7)

• Risk of misinterpretation: Non-fluorescing tissue in the surgical field does not rule out the presence of tumor. (5.2, 14)

1 INDICATIONS AND USAGE

Gleenan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. (1)

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

For oral use only

• The recommended oral dose of reconstituted Gleenan is 20 mg/kg body weight. More than 1 vial may be required.

2.2 Reconstitution of Gleenan

Gleenan powder must be reconstituted prior to administration by a healthcare provider according to the following instructions:

- Determine the total number of vials needed to achieve the intended dose for the patient according to the equation below (rounded up to the nearest whole vial):

\[
\text{Number of vials} = \left\lceil \frac{\text{Patient Body Weight (kg)}}{75 \text{ kg/vial}} \right\rceil
\]

- Completely remove the white cap and aluminum crimp seal from each vial.

- Remove and retain the rubber stopper from the vial.

- Using a disposable volumetric syringe, remove the administration volume of reconstituted Gleolan solution from the dosing container and transfer to a separate dosing syringe, measure 50 ml of drinking water and add to each vial containing 1,500 mg of Gleolan.

- Gently swirl the vial to completely dissolve the powder.

- The reconstituted solution (10 mg of Gleolan per ml) is clear and colorless to slightly yellowish.

- If required, replace the stopper and store reconstituted solution for up to 24 hours at room temperature prior to administration.

2.3 Gleenan Administration

Gleenan is for ORAL USE ONLY. The reconstituted Gleenan solution is administered according to the following steps:

- Calculate the administration volume, in ml, to achieve the intended dose according to the following equation:

\[
\text{Administration Volume (ml)} = \frac{\text{Patient Body Weight (kg)}}{75 \text{ kg/vial}} \times 50 \text{ mg/ml}
\]

- Transfer the entire contents of the prepared vial(s) into an appropriate dosing container (e.g., oral medicine bottle) ensure the entire contents of the vials are transferred.

- After transfer, discard the empty vial(s).

- Using a disposable volumetric syringe, remove the administration volume of reconstituted Gleenan solution from the dosing container and transfer to a separate oral dosing container.

- Discard unused volume of Gleenan solution.

- Administer orally 3 hours (range 2 to 4 hours) prior to induction of anesthesia.

2.4 Imaging Instructions

Gleenan must be used with a standard surgical operating microscope adapted with a blue light emitting light source (power density 40-80 mW/cm²) and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelength of 375 to 440 nm and for observation from 620 to 710 nm. Filters transmit porphyrin fluorescence in excitation and emission, as well as a fraction of backscattered blue excitation light necessary for distinguishing non-fluorescing tissue.

Gleenan should only be used by neurosurgeons who have completed a training program on use of fluorescence in surgery. Training is provided by the distributor.

3 DOSAGE FORMS AND STRENGTHS

For oral solution: 1,500 mg aminolevulinic acid hydrochloride (ALA HCl) lyophilized powder, equivalent to 1,770 mg aminolevulinic acid (ALA), in a 50 ml single-dose clear, colorless, glass vial with rubber stopper. After reconstitution with 50 ml drinking water, the solution contains 30 mg per ml of aminolevulinic acid hydrochloride (equivalent to 23.4 mg per ml of aminolevulinic acid) and is clear and colorless to slightly yellowish in color.

4 CONTRAINDICATIONS

- Hypersensitivity to aminolevulinic acid (ALA) or porphyrins. (See Warnings and Precautions [5.3])

- Acute or chronic types of porphyria, due to potential ineffectiveness of the drug in these patients.

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Phototoxic Reaction

Due to the risk of phototoxic reactions, do not administer phototoxic drugs (St. John’s wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolines and tetracyclines), and topical preparations containing ALA for 24 hours during the perioperative period (See Drug Interactions [7.2]). Reduce exposure to sunlight or room lights for 48 hours after administration of Gleenan.

5.2 Risk of Misinterpretation

Errors may occur with the use of Gleenan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma (See Clinical Studies [7.1]). Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

5.3 Hypersensitivity Reactions

Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria (See Contraindications [4], Adverse Reactions [6.2]). Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of Gleenan is supported by data from 5 open label clinical studies, which included 127 patients with glioma who received AHA HCl. Adverse reactions that occurred in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting. Adverse reactions occurring in the first 6 weeks after surgery in <1% of patients were: chills, phototoxic reaction, solar dermatitis, hypotension, abnormal liver function test, and diarrhea. One patient experienced respiratory failure due to drug overdose (See Overdosage [10]).

6.2 Post Marketing Experience

Nervous system disorders occurred in 29% of patients within the first week after surgery. Events occurring in >1% of patients included aphasia (6%), hemiparesis (7.8%), hemianopsia (13.2%), headache (12.7%), seizures (11.2%), hemiplegia (17.6%), sensory loss (13.8%), and hemianopia (2.1%). No cases of liver failure occurred.

Neurologic Events

Worsening of 2 Common Toxicity Criteria (CTC) grades in alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) occurred in 15.8% and 11.6%, respectively, within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal (ULN) for each parameter. At week 6, ALT remained elevated in 2.9% of patients (range 2 to greater than 5 X ULN), and GGT was elevated in 7.5% of patients (range 2 to greater than 10 X ULN). No cases of liver failure occurred.
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available human data on Gleolan in pregnant women to inform a drug associated risk of adverse developmental outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral ALA HCI administration to pregnant rabbits during organogenesis at doses 3 times the maximum recommended human oral dose (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Animal data

ALA HCI was administered to rats at oral doses of 15, 50 and 130 mg/kg/day (approximately 0.1, 0.6, and 3 times the maximum human recommended dose [MRHD], respectively based on AUC comparisons) from gestation days 6-18. The no-observed-adverse-effect level (NOAEL) for maternal toxicity was 50 mg/kg/day (approximately 0.1 times the MRHD) and the NOEL for embryo-fetal developmental toxicity was 150 mg/kg/day.

8.2 Lactation

Risk summary

There are no data on the presence of ALA HCI in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Gleolan and any potential adverse effects on the breastfed infant from Gleolan from the underlying maternal condition.

Clinical Considerations

To decrease exposure to Gleolan to the breastfed infant, advise a lactating woman to pump and discard breast milk after the administration of Gleolan for 24 hours (i.e., 5 to 6 half-lives).

8.4 Pediatric Use

The safety and effectiveness of Gleolan in pediatric patients have not been established.

8.5 Geriatric Use

51 of 57 subjects in clinical studies of Gleolan, 182 were 65 to <75 years of age and 7 were ≥75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. No dose adjustment is required in elderly patients.

8.6 Patients with Renal Impairment

Because approximately one third of the ALA dose is excreted in urine as parent drug, ALA clearance may be reduced in patients with renal impairment; it is not known if dose adjustment is needed [see Clinical Pharmacology (12.3)].

8.7 Patients with Hepatic Impairment

The contribution of the liver to the elimination of ALA following Gleolan dosing is unknown. ALA clearance may be reduced in patients with hepatic impairment; it is not known if dose adjustment is needed [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE

Overdosage has been associated with respiratory insufficiency and erythema. In the event of overdose, supportive measures should be provided as necessary, including protection from strong light sources.

11 DESCRIPTION

11.1 Chemical Properties

Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent for oral use. The 30-mL, clear vial contains 1.500 mg of tetrasodium aminolevulinic acid HCI powder (equivalent to 1,170 mg aminolevulinic acid). After reconstitution, the product has a concentration of 30 mg aminolevulinic acid hydrochloride per mL (equivalent to 23.4 mg aminolevulinic acid per mL). The chemical name is 5-amino-4-oxo-pentanoic acid hydrochloride. The chemical formula for aminolevulinic acid hydrochloride is C8H7ClNO4. Its molecular weight is 167.59 g/mol with the following structural formula:

\[
\text{C8H7ClNO4} \quad (\text{Molecular Weight: 167.59 g/mol})
\]

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

ALA occurs endogenously as a metabolite that is formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of ALA leads to accumulation of ALA in the liver and to the formation of Pp IX in tumor cells. The reason for the accumulation of Pp IX in neoplastic tissue is not known.

During glioma surgery, Gleolan is used with an operating microscope adapted with a blue emitting light source (power density 40-80 mW/cm² and filter set for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm). This allows tumor tissue to be visualized as red fluorescence. Tissue lacking sufficient Pp IX concentrations appears blue.

12.2 Pharmacodynamics

The effect of the timing of the Gleolan dosing on fluorscence intensity in brain tissue is unknown. The relationship between systemic ALA plasma concentrations at the time of visualization and fluorescence intensity in brain tissue is also unknown. The dose of 20 mg/kg provided stronger ALA-induced fluorescence in glioma tissue by both visual and spectrophotometric assessment compared to lower doses tested.

Cardiac Electrophysiology

Administration of the approved recommended dose of Gleolan did not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics

In 12 healthy subjects, the mean half-life of ALA following the recommended dose of Gleolan solution was 0.9 ± 1.2 hours (mean ± std dev) with a range of 0.3 to 1.3 hours. Maximun ALA plasma concentrations of the Pp IX metabolite (Tmax) for Pp IX occurred with a median of 4 hours and a range of 1.2 to 7.8 hours. The elimination half-life of Pp IX was 3.6 ± 1.8 hours (mean ± std dev) with a range of 1.2 to 7.8 hours.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No carcinogenicity studies have been conducted with Gleolan.

Mutagenesis

ALA HCI was not mutagenic in the Ames assay, HPIR-979 mammalian cell mutagenicity test, the peripheral human lymphocyte chromosomal aberration assay and the in vivo mouse micronucleus test when studies were performed in the dark or under subdued lighting.

Impairment of fertility

No fertility studies have been conducted with Gleolan.

14 CLINICAL STUDIES

The efficacy of 20 mg/kg ALA HCI was evaluated in 3 clinical studies (Study 1-3) involving patients, ages 18 to 75 years old, who had a presurgical MR with high-grade glioma (WHO Grade III or IV) and who were undergoing surgical resection. Study 1 was an open-label study of 31 patients with newly diagnosed high-grade glioma and Study 2 was an open-label study of 36 patients with recurrent high-grade glioma. In Studies 1 and 2, after initial debulking was carried out under white light, biopsies were obtained under fluorescence light from fluorescent and nonfluorescent sites. Presence of fluorescence (positive/negative) was compared to tumor status (true/false) using histopathology as the reference standard. True positives and false negatives among fluorescent biopsies and true negatives and false positives among nonfluorescent biopsies are provided in Table 1.

Study 3 was a randomized, multicenter study in 415 patients with a presurgical diagnosis of high-grade glioma by MRI. Patients were randomized in 1:1 ratio to ALA fluorescence arm or to white light control arm. Biopsies were obtained from tumor-core, tumor-margin and regions just distant to the tumor margins. In 349 patients high grade glioma was confirmed by a blinded central read and histopathology. The remaining patients were diagnosed with metastatic disease, abscess, low-grade glioma or other conditions.

In patients with confirmed high-grade glioma randomized to the ALA fluorescence arm, presence of fluorescence at a biopsy level was compared to tumor status using histopathology as the reference standard (Table 1). In 4 patients with low-grade glioma (WHO Grade I or II) who received ALA HCI, 9 out of 10 biopsies were false negative.

The extent of resection among patients with confirmed high-grade glioma in the ALA fluorescence arm was compared to that among patient in the control arm, with the "completeness" of resection being determined by a central blinded read of early post-surgical MRI. Percentage of patients who had "completeness" of resection was 64% in the ALA arm and 38% in the control arm, with the difference of 26% [95% CI: (16%, 36%)].

Table 1. Presence of Fluorescence Compared to Histopathology (biopsy level)

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of Fluorescent Biopsies</th>
<th>Number of Nonfluorescent Biopsies</th>
<th>True Positive</th>
<th>False Positive</th>
<th>True Negative</th>
<th>False Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1</td>
<td>185</td>
<td>112</td>
<td>178</td>
<td>7</td>
<td>27</td>
<td>85</td>
</tr>
<tr>
<td>Study 2</td>
<td>354</td>
<td>116</td>
<td>342</td>
<td>12</td>
<td>30</td>
<td>13</td>
</tr>
<tr>
<td>Study 3</td>
<td>319</td>
<td>160</td>
<td>312</td>
<td>7</td>
<td>30</td>
<td>13</td>
</tr>
</tbody>
</table>

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Gleolan (NDC 59137-231-01) is supplied as 1,500 mg of L-hydroxymethylpyrrolidinyl acetic acid hydrochloride powder (equivalent to 1,170 mg aminolevulinic acid), for oral solution in a 30-mL clear, colorless, glass vial with a rubber stopper and an aluminum/stamp seal.

16.2 Storage and Handling

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).

17 PATIENT COUNSELING INFORMATION

Advise patients that they may experience elevated liver enzymes (ALT and GGT) within the first week after surgery. This elevation may persist for 6 weeks. Advise patients to reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan due to risk of phototoxic reactions.

Manufactured by: NK Development Corp., Lexington, KY 40503

Distributed by: Meadox Pharma, Inc, Chicago, IL 60606

Product of Germany